Skip to main content

Table 4 Clinical outcomes

From: Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis

  Values 95% CI
Median TTF Gem (mo) 11.50 9 – 14.3
Median OS (mo) 26.90 18 – 32
OS 2 yr (%) 56.40 NA
N° of chemo lines   
Median 1 (1 – 6) NA
  1. TTF Gem = Time to Treatment Failure on gemcitabine; OS = Overall Survival; OS 2 yr = 2-year Overall Survival; No of chemo lines = Number of chemotherapeutic lines; 95% CI = 95% Confidence Interval.